Infectious causes of dementia
Cheryl A. Jay
University of California, San Francisco, San Francisco, CA, USA
San Francisco General Hospital (SFGH), San Francisco, CA, USA
Search for more papers by this authorEmily L. Ho
University of Washington, Seattle, WA, USA
Swedish Neuroscience Institute, Seattle, WA, USA
Search for more papers by this authorJohn Halperin
Atlantic Neuroscience Institute, Summit, NJ, USA
Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA
Overlook Medical Center, Summit, NJ, USA
Search for more papers by this authorCheryl A. Jay
University of California, San Francisco, San Francisco, CA, USA
San Francisco General Hospital (SFGH), San Francisco, CA, USA
Search for more papers by this authorEmily L. Ho
University of Washington, Seattle, WA, USA
Swedish Neuroscience Institute, Seattle, WA, USA
Search for more papers by this authorJohn Halperin
Atlantic Neuroscience Institute, Summit, NJ, USA
Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA
Overlook Medical Center, Summit, NJ, USA
Search for more papers by this authorMichael D. Geschwind MD PhD
Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorCaroline Racine Belkoura PhD
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorSummary
Cognitive and neuropsychological dysfunction heralding acute cerebral infection typically evolves to delirium or coma over hours to days, excluding neurodegenerative disorders as a tenable diagnosis. For a few more indolent infections, dementia is sometimes the presenting or predominant feature. Currently, human immunodeficiency virus-associated dementia is likely the most common infectious cause of dementia, a distinction held by general paresis, the cerebral form of tertiary syphilis, for the prior century. Behavioral and cognitive disturbances are also presenting manifestations of subacute sclerosing panencephalitis, an infection with defective measles virus, and Whipple's disease, caused by the bacterium Tropheryma whipplei. Neuropsychological dysfunction is occasionally a prominent and relatively isolated presenting manifestation of cryptococcal meningitis and neurocysticercosis. Memory and concentration difficulties are common in patients with hepatitis C infection, Lyme disease, and prior West Nile virus infection. Neurobehavioral disorders may also be sequelae of acute brain infections, including community-acquired acute bacterial meningitis and viral encephalitis.
References
- Ginsberg L, Kidd D. Chronic and recurrent meningitis. Pract Neurol 2008; 8: 348–361.
- Helbok R, Broessner G, Pfausler B, Schmutzhard E. Chronic meningitis. J Neurol 2009; 256: 168–175.
- Snider WD, Simpson DM, Nielsen S et al. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983; 14: 403–418.
- Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. clinical features. Ann Neurol 1986; 19: 517–24.
- Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Ann Neurol 1986; 19: 525–535.
- Centers for Disease Control and Prevention. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Morb Mortal Wkly Rep 1987; 36 (suppl 1S): 3S–15S.
- McArthur JC. Neurologic manifestations of AIDS. Medicine 1987; 66: 407–437.
- Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988; 158: 1079–1083.
- Singer EJ, Valdes-Sueiras M, Commins D, Levine A. Neurologic presentations of AIDS. Neurol Clin 2010; 28: 253–275.
- McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 2010; 67: 699–714.
- Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007; 27: 86–92.
- Janssen RS, Cornblath DR, Epstein LG et al. Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection: report of a working group of the American Academy of Neurology AIDS task force. Neurology 1991; 41: 778–785.
- Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8 (suppl 2): 115–121.
- Monforte AD, Cinque P, Mocroft A et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55: 320–328.
- Valcour V, Paul R. HIV infection and dementia in older adults. Clin Infect Dis 2006; 42: 1449–1454.
- Antinori A, Arendt G, Becker JT et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789–1799.
- Zunt JR, Tu RK, Anderson DM et al. Progressive multifocal leukoencephalopathy presenting as human immunodeficiency virus type 1 (HIV)-associated dementia. Neurology 1997; 49: 263–265.
- Arendt G, Hefter H, Figge C et al. Two cases of cerebral toxoplasmosis in AIDS patients mimicking HIV-related dementia. J Neurol 1991; 238: 439–442.
- Fiala M, Singer EJ, Graves MC et al. AIDS dementia complex complicated by cytomegalovirus encephalopathy. J Neurol 1993; 240: 223–231.
- Griffiths P. Cytomegalovirus infection of the central nervous system. Herpes 2004; 11 Suppl 2: 95A–104A.
- Navia BA, Price RW. The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. Arch Neurol 1987; 44: 65–69.
- Costello D, Davis J, Venna N. HIV infection with immunodeficiency presenting with subacute cognitive decline: recent illustrative cases. CNS Spectr 2007; 12: 842–850.
- Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV-1 infection. J Infect Dis 2008; 197 Suppl 3: S294–S306.
- Spudich SS, Nilsson AC, Lollo ND et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5: 98.
- Marra CM, Maxwell CL, Collier AC et al. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis 2007; 7: 37.
- Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65–70.
- Garg RK. Subacute sclerosing panencephalitis. J Neurol 2008; 255: 1861–1871.
- Prashanth LK, Taly AB, Ravi V et al. Adult onset subacute sclerosing panencephalitis: clinical profile of 39 patients from a tertiary care centre. J Neurol Neurosurg Psychiatry 2006; 77: 630–633.
- Gagnon A, Bouchard RW. Fulminating adult-onset subacute sclerosing panencephalitis in a 49-year-old man. Arch Neurol 2003; 60: 1160–1161.
- Tan E, Namer IJ, Ciger A et al. The prognosis of subacute sclerosing panencephalitis in adults: report of 8 cases and review of the literature. Clin Neurol Neurosurg 1991; 93: 205–209.
- Frings M, Blaeser I, Kastrup O. Adult-onset subacute sclerosing panencephalitis presenting as a degenerative dementia syndrome. J Neurol 2002; 249: 942–943
- Mawrin C, Lins H, Koenig B et al. Spatial and temporal disease progression of adult-onset subacute sclerosing panencephalitis. Neurology 2002; 58: 1568–1571.
- Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol 2010; 36: 91–133.
- Sene D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 2004; 19: 357–381.
- Acharya JN, Pacheco VH. Neurologic complications of hepatitis C. Neurologist 2008; 14: 151–156.
- Forton DM, Taylor-Robinson SD, Thomas HC. Central nervous system changes in hepatitis C virus infection. Eur J Gastroenterol Hepatol 2006; 18: 333–338.
- Forton DM, Allsop JM, Main J et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358: 38–39.
- Ryan EL, Morgello S, Isaacs K et al. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004; 62: 957–962.
- Clifford DB, Smurzynski M, Park LS et al. Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology 2009; 73: 309–314.
- Soogoor M, Lynn HS, Donfield SM et al. Hepatitis C virus infection and neurocognitive function. Neurology 2006; 67: 1482–1485.
- Laskus T, Radkowski M, Adair DM et al. Emerging evidence of hepatitis C virus neuroinvasion. AIDS 2005; 19 (suppl 3): S140–144.
- Tunkel AR, Glaser CA, Bloch KC et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47: 303–327.
- Hokkanen L, Poutiainen E, Valanne L et al. Cognitive impairment after acute encephalitis: comparison of herpes simplex and other aetiologies. J Neurol Neurosurg Psychiatry 1996; 6: 478–484.
- Kaplan CP, Bain KP. Cognitive outcome after emergent treatment of herpes simplex encephalitis with acyclovir. Brain Inj 1999; 13: 935–941.
- Hokkanen L, Launes J. Cognitive outcome in acute sporadic encephalitis. Neuropsychol Rev 2000; 10: 151–167.
- Utley TFM, Ogden JA, Gibb A et al. The long-term neuropsychological outcome of herpes simplex encephalitis in a series of unselected survivors. Neuropsychiatry Neuropsychol Behav Neurol 1997; 10: 180–189.
- Gyure KA. West Nile virus infections. J Neuropathol Exp Neurol 2009; 68: 1053–1060.
- Sejvar JJ, Curns AT, Welburg L et al. Neurocognitive and functional outcomes in persons recovering from West Nile virus illness. J Neuropsychol 2008; 2: 477–499.
- Gustaw-Rothenberg K. Cognitive impairment after tick-borne encephalitis. Dement Geriatr Cogn Disord 2008; 26: 165–168.
- Hokkanen L, Launes J. Cognitive recovery instead of decline after acute encephalitis; a prospective follow up study. J Neurol Neurosurg Psychiatry 1997; 63: 222–227.
- Centers for Disease Control and Prevention. Outbreak of syphilis among men who have sex with men–Southern California, 2000. MMWR Morb Mortal Wkly Rep 2001; 50: 117–120.
- Centers for Disease Control and Prevention. Primary and secondary syphilis among men who have sex with men–New York City, 2001. MMWR Morb Mortal Wkly Rep 2002. 51: 853–856.
- Centers for Disease Control and Prevention. Internet use and early syphilis infection among men who have sex with men–San Francisco, California, 1999–2003. MMWR Morb Mortal Wkly Rep 2003. 52: 1229–1232.
- Centers for Disease Control and Prevention. Trends in primary and secondary syphilis and HIV infections in men who have sex with men–San Francisco and Los Angeles, California, 1998–2002. MMWR Morb Mortal Wkly Rep 2004. 53: 575–578.
- JD Klausner and EW Hook eds. Current diagnosis and treatment of sexually transmitted diseases, 1st ed. New York: McGraw-Hill, 2007.
- Merritt HH, Adams RD, Solomon HC. Neurosyphilis, Oxford University Press: New York, 1946.
- Brown EM. French psychiatry's initial reception of Bayle's discovery of general paresis of the insane. Bull Hist Med 1994; 68: 235–53.
- Brandst AM. No magic bullet: a social history of venereal disease in the United States since 1880. Oxford University Press: New York, 1987.
- Brown, EM. Why Wagner-Jauregg won the Nobel Prize for discovering malaria therapy for general paresis of the insane. Hist Psychiatry 2000; 11: 371–382.
- Stokes JH, Beerman H, Ingraham HR. Modern clinical syphilology, 3rd ed. WB Saunders: Philadelphia, 1944
- Hahn RD, Webster B, Weickhard G et al. Penicillin treatment of general paresis (dementia paralytica). Arch Neurol Psychiatry 1959; 81: 557–90.
- Storm-Mathisen A. General paresis; a follow-up study of 203 patients. Acta Psychiatr Scand 1969; 45(2): 118–32.
- (a) Dewhurst K. The neurosyphilitic psychoses today. A survey of 91 cases. Br J Psychiatry 1969; 115: 31–8; (b) Herring AJ, Ballard RC, Pope V, et al. A multi-centre evaluation of nine rapid, point-of-care syphilis tests using archived sera. Sex Transm Infect 2006; 82 Suppl 5: v7–12.
- (a) Mabey D, Peeling RW, Ballard R, et al. Prospective, multi-centre clinic-based evaluation of four rapid diagnostic tests for syphilis. Sex Transm Infect 2006; 82 Suppl 5: v13–6; (b) Gurses C, Bilgic B, Topcular B et al. Clinical and magnetic resonance imaging findings of HIV-negative patients with neurosyphilis. J Neurol 2007; 254: 368–74.
- Zhang SQ, Wan B, Ma XL, Zheng HM. Worsened MRI findings during the early period of treatment with penicillin in a patient with general paresis. J Neuroimaging 2008. 18: 360–3.
- Fadil H, Gonzalez-Toledo E, Kelley BJ, Kelley RE. Neuroimaging findings in neurosyphilis. J Neuroimaging 2006; 16: 286–9.
- Peng F, Hu X, Zhong X et al. CT and MR findings in HIV-negative neurosyphilis. Eur J Radiol 2008. 66: 1–6.
- Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. MMWR Morb Mortal Wkly Rep 2005; 55 (RR11): 22–35.
- Garin C, Bujadoux A. Paralysie par les tiques. J Med Lyon 1922; 71: 765–767.
- Hellerstrom S. Erythema migrans Afzelius with meningitis. Acta Derm Venereol 1951; 31: 227–234.
- Steere AC, Malawista SE, Hardin JA et al. Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum. Ann Intern Med 1977; 86: 685–698.
- Benach JL, Bosler EM, Hanrahan JP et al. Spirochetes isolated from the blood of two patients with Lyme Disease. N Engl J Med 1983; 308: 740–742.
- Steere AC, Grodzicki RL, Kornblatt AN et al. The spirochetal etiology of Lyme Disease. N Engl J Med 1983; 308: 733–740.
- Reik L, Steere AC, Bartenhagen NH et al. Neurologic abnormalities of Lyme disease. Medicine 1979; 58: 281–294.
- Asbrink E, Hederstedt B, Hovmark A. The spirochetal etiology of acrodermatitis chronica atrophicans Herxheimer. Acta Derm Venereol 1984; 64: 506–512.
- Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme Disease—United States, 1992–2006. Morb Mortal Wkly Rep 2008; 57: 1–9.
- Anonymous. Recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme Disease. Morb Mortal Wkly Rep 1995; 44: 590–591.
- Meer-Scherrer L, Chang Loa C, Adelson ME et al. Lyme disease associated with Alzheimer's disease. Curr Microbiol 2006; 52: 330–332.
- Halperin JJ, Krupp LB, Golightly MG, Volkman DJ. Lyme borreliosis-associated encephalopathy. Neurology 1990; 40: 1340–1343.
- Fenollar F, Puechal X, Raoult D. Whipple's disease. N Engl J Med 2007; 356: 55–66.
- Schneider T, Moos V, Loddenkemper C et al. Whipple's disease: new aspects of pathogenesis and treatment. Lancet Infect Dis 2008; 8: 179–190.
- Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 1992; 327: 293–301.
- Raoult D, Birg ML, La Scola B et al. Cultivation of the bacillus of Whipple's disease. N Engl J Med 2000; 342: 620–625.
- Gerard A, Sabrot-Reynauld F, Liozon E et al. Neurologic presentation of Whipple disease. Medicine 2002 ; 81: 443–457.
- Louis ED, Lynch T, Kaufmann P et al. Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol 1996; 40: 561–568.
- Rossi T, Haghighipour R, Haghighi M et al. Cerebral Whipple's disease as a cause of reversible dementia. Clin Neurol Neurosurg 2005; 107: 258–261.
- Benito-Leon J, Sedano LF, Louis ED. Isolated central nervous system Whipple's disease causing reversible frontotemporal-like dementia. Clin Neurol Neurosurg 2008; 110: 747–749.
- van de Beek D, Schmand B, de Gans J et al. Cognitive impairment in adults with good recovery after bacterial meningitis. J Infect Dis 2002; 186: 1047–1052.
- Weisfelt M, van de Beek D, Hoogman M et al. Cognitive outcome in adults with moderate disability after pneumococcal meningitis. J Infect 2006; 52: 433–439.
- Hoogman M, van de Beek D, Weisfelt M et al. Cognitive outcome in adults after bacterial meningitis. J Neurol Neurosurg Psychiatry 2007; 78: 1092–1096.
- Merkelbach S, Sittinger H, Schweizer I, Muller M. Cognitive outcome after bacterial meningitis. Acta Neurol Scand 2000; 102: 118–123.
- Weisfelt M, Hoogman M, van de Beek D et al. Dexamethasone and long-term outcome in adults with bacterial meningitis. Ann Neurol 2006; 60: 456–468.
- Schmand B, de Bruin E, de Gans J, van de Beek D. Cognitive functioning and quality of life nine years after bacterial meningitis. J Infect 2010; 61: 330–334.
- Chaykulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2006; 20: 507–544.
- Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 291–322.
- Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS 2007; 21: 2119–2129.
- Steiner I, Polacheck I, Melamed E. Dementia and myoclonus in a case of cryptococcal encephalitis. Arch Neurol 1984; 41: 216–217.
- Aharon-Peretz J, Kliot D, Finkelstein R et al. Cryptococcal meningitis mimicking vascular dementia. Neurology 2004; 62: 2135.
- Ala TA, Doss RC, Sullivan CJ. Reversible dementia: a case of cryptococcal meningitis masquerading as Alzheimer's disease. J Alzheimers Dis 2004; 6: 503–508.
- Hoffmann M, Muniz J, Carroll E, De Villasante J. Cryptococcal meningitis misdiagnosed as Alzheimer's disease: complete neurological and cognitive recovery with treatment. J Alzheimers Dis 2009; 16: 517–520.
- Carpio A. Neurocysticercosis: an update. Lancet Infect Dis 2002; 2: 751–762.
- Garcia HH, Del Brutto OH. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005; 4: 653–651.
- Sinha S, Sharma BS. Neurocysticercosis: a review of current status and management. J Clin Neurosci 2009; 16: 867–876.
- Sotelo J, Guerrero V, Rubio F. Neurocysticercosis: a new classification based on active and inactive forms. Arch Int Med 1985; 145: 442–445.
- Singh S, Dhikav V, Agarwal N, Anand KS. An unusual cause of psychosis. Lancet 2004; 363: 1522.
- Patel R, Jha S, Yadav RK. Pleomorphism of the clinical manifestations of neurocysticercosis. Trans R Soc Trop Med Hyg 2006; 100: 134–141.
- Forlenza OV, Filho AHGV, Nobrega JPS et al. Psychiatric manifestations of neurocysticercosis: a study of 38 patients from a neurology clinic in Brazil. J Neurol Neurosurg Psychiatry 1997; 62: 612–612.
- Ciampi de Andrade D, Rodrigues CL, Abraham R et al. Cognitive impairment and dementia in neurocysticercosis: a cross-sectional controlled study. Neurology 2010; 74: 1288–1295.
- Abba K, Ramaratnam S, Ranganathan LN. Antihelminthics for people with neurocysticercosis. Cochrane Database Syst Rev 2010; 3: CD000215.
- Baird RA, Wiebe S, Zunt JR et al. Evidence-based guideline: treatment of parenchymal neurocysticercosis. Neurology 2013; 80: 1424–1429.
- Ramirez-Bermudez J, Higuera J, Sosa AL et al. Is dementia reversible in patients with neurocysticercosis? J Neurol Neurosurg Psychiatry 2005; 76: 1164–1166.